MyFinsight
Home
Blog
About
Contact
Download
Download image
Affordable Medicines
Segment
$1,745,524K
(3.58%↑ Y/Y)
Av KARESegment
$744,728K
(12.34%↑ Y/Y)
Specialty Segment
$528,508K
(18.57%↑ Y/Y)
Net revenue
$3,018,760K
(8.05%↑ Y/Y)
Gross profit
$1,113,308K
(9.10%↑ Y/Y)
Other operating
income
$5,240K
Cost of goods sold
$1,905,452K
(7.44%↑ Y/Y)
(credit) charges related
to legal matters,...
$390K
(100.40%↑ Y/Y)
Operating income
$394,096K
(58.06%↑ Y/Y)
Selling, general and
administrative
$526,827K
(10.58%↑ Y/Y)
Research and development
$186,175K
(-2.38%↓ Y/Y)
Intellectual property legal
development expenses
$7,632K
(30.57%↑ Y/Y)
Restructuring and other
charges
$4,208K
(78.68%↑ Y/Y)
Income (loss) before
income taxes
$139,209K
(353.05%↑ Y/Y)
Total other expense,
net
-$254,887K
(16.25%↑ Y/Y)
Other income, net
$16,522K
(40.23%↑ Y/Y)
Foreign exchange gain
(loss), net
$7,635K
(211.52%↑ Y/Y)
Net income (loss)
$127,933K
(273.17%↑ Y/Y)
Provision for income taxes
$11,276K
(-40.22%↓ Y/Y)
Interest expense, net
-$241,091K
(6.77%↑ Y/Y)
Loss on refinancing
-$31,365K
Increase in tax
receivable agreement...
-$6,588K
(87.00%↑ Y/Y)
Net income (loss)
attributable to amneal...
$72,057K
Less net income
attributable to...
$55,876K
(29.91%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Amneal Pharmaceuticals, Inc. (AMRX)
Amneal Pharmaceuticals, Inc. (AMRX)